1. Generics Bulletin
  2. >>Products

Amgen Sees Plenty Of Interest In US Eylea Biosimilar, Buoyed By Strong Supply Chain

Retina Teams Deployed As Amgen Awaits News On Permanent Reimbursement Codes

 
• By Dean Rudge

All eyes are on Eylea, after Amgen said last week that it would launch the first US biosimilar in the face of ongoing litigation. The California-based player has spoken of its prospects in the wet-AMD space, including a desire to chart its own path amid supply shortages for Avastin.

Rocket_Launch
• Source: Shutterstock

Well accustomed by now to finding itself in the vanguard of big-ticket biosimilar launches, Amgen says it has fully deployed its teams in support of the firm’s recent launch of the first US biosimilar to Regeneron’s Eylea (aflibercept) 2mg, and has hitherto been encouraged by “enthusiastic” feedback from customers.

The California-based biotech expects “strong interest” in its Pavblu (aflibercept-ayyh) biosimilar, following confirmation last week that Regeneron’s failure to secure an injunction against the biosimilar pending appeal had provided the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Generics Bulletin

Formycon Hopes Stelara Biosimilar Sales To Pull Through FY2025 As Q1 Revenues Slump

 
• By Urtė Fultinavičiūtė

Formycon said it predicted low earnings in the first quarter of 2025, after enjoying milestone payments last year. Now, the pressure is on the growing biosimilars portfolio to pull the company through this year.

Gedeon Richter Feels Biosimilar Model ‘Is Looking For An Equilibrium’

 
• By Dean Rudge

Gedeon Richter’s CEO weighed in on the pricing landscape for biosimilars as the firm admitted the market for biosimilar denosumab was set to be more crowded than it had initially anticipated.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.